Shares of Omeros Corporation (NASDAQ:OMER) have earned an average rating of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $36.17.
A number of brokerages have weighed in on OMER. HC Wainwright set a $30.00 target price on shares of Omeros and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. Zacks Investment Research downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $19.00 target price (up from $15.00) on shares of Omeros in a research note on Thursday, August 24th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $24.00 target price on shares of Omeros in a research note on Friday, October 27th.
Shares of Omeros (OMER) traded up $0.24 during mid-day trading on Thursday, reaching $19.82. 474,400 shares of the company traded hands, compared to its average volume of 798,857. Omeros has a 12-month low of $8.71 and a 12-month high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to the consensus estimate of $17.82 million. During the same period in the prior year, the firm posted ($0.34) earnings per share. The company’s revenue was up 91.9% on a year-over-year basis. equities research analysts expect that Omeros will post -0.98 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ingalls & Snyder LLC raised its stake in shares of Omeros by 0.3% during the third quarter. Ingalls & Snyder LLC now owns 5,161,035 shares of the biopharmaceutical company’s stock worth $111,582,000 after buying an additional 17,746 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Omeros by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after buying an additional 94,280 shares during the last quarter. State Street Corp raised its stake in shares of Omeros by 7.3% during the second quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after buying an additional 66,827 shares during the last quarter. Northern Trust Corp raised its stake in shares of Omeros by 6.4% during the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after buying an additional 34,328 shares during the last quarter. Finally, Tocqueville Asset Management L.P. raised its stake in shares of Omeros by 0.7% during the third quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after buying an additional 3,430 shares during the last quarter. 49.85% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/12/07/omeros-corporation-omer-given-average-recommendation-of-buy-by-brokerages.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.